Showing results (221-230 of 270) with videos related to
Sort By:
Pageof 27
Cancer Immunology, Immunotherapy : CII|January 8, 2021
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinomaPedro Rocha, Ruth Salazar, Jiexin Zhang, et al.The New England Journal of Medicine|October 17, 2025
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung CancerXiuning Le, Tae Min Kim, Herbert H Loong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)Xiuning Le, Jyoti D Patel, Elaine Shum, et al.Journal for Immunotherapy of Cancer|July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trialMehmet Altan, Yan Wang, Juhee Song, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 18, 2026
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIsMonique B Nilsson, Xiuning Le, Alissa Poteete, et al.Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.Pageof 27